◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

CELLDEX THERAPEUTICS, INC.

CIK: 744218 SIC: 2835
$2.97M
Revenue
$-258.76M
Net Income
-
Gross Margin
-9675.62%
Op. Margin
$-367.67M
Free Cash Flow
Financial Statements Quarterly (10-Q)
Showing 7 of 44 quarterly reports available
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
+ Total Revenue $121.00K $1.42M $730.00K $695.00K $1.18M $3.19M $2.50M
Revenue Growth % (YoY) -89.7% -55.4% -70.8% nan% nan% nan% nan%
Operating Expenses $87.27M $73.62M $64.59M $63.43M $57.20M $55.32M $48.81M
Research & Development $75.33M $62.93M $54.20M $52.61M $46.94M $45.26M $39.69M
+ Operating Income $-87.15M $-73.62M $-63.86M $-62.74M $-56.03M $-52.13M $-46.32M
Operating Margin % -72027.3% -5169.7% -8747.5% -9027.2% -4768.3% -1633.5% -1854.2%
+ Net Income $-81.32M $-67.04M $-56.60M $-53.80M $-47.09M $-42.12M $-35.84M
Net Margin % -67204.1% -4708.1% -7753.4% -7740.4% -4007.8% -1320.0% -1434.8%
Basic EPS -1.23 -1.01 -0.85 -0.81 -0.71 -0.64 -0.54
Diluted EPS -1.23 -1.01 -0.85 -0.81 -0.71 -0.64 -0.54
Basic Shares Outstanding - 66K 66K 66K 658 66K 66K
Diluted Shares Outstanding - 66K 66K 66K 658 66K 66K
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Cash & Cash Equivalents $28.87M $36.04M $23.04M $17.14M $28.36M $36.40M $42.74M
Short-term Investments $489.70M $547.19M $607.29M $656.15M $696.92M $719.60M $759.58M
Other Current Assets $14.08M $21.03M $17.98M $19.40M $21.18M $21.99M $8.12M
Total Current Assets $534.66M $604.34M $648.40M $693.76M $747.16M $778.84M $811.98M
Property Plant & Equipment $5.33M $4.83M $4.39M $4.60M $4.35M $4.23M $3.86M
Intangible Assets $27.19M $27.19M $27.19M $27.19M $27.19M $27.19M $27.19M
Other Non-current Assets $13.36M $9.36M $9.30M $10.41M $9.75M $9.75M $107.00K
Total Assets $582.98M $648.44M $692.41M $739.47M $792.34M $823.18M $845.59M
Accounts Payable $1.18M $4.27M $2.07M $3.41M $3.27M $1.11M $3.80M
Accrued Liabilities $47.03M $39.72M $28.42M $25.46M $33.84M $28.20M $18.59M
Other Current Liabilities $1.23M $930.00K $930.00K $1.65M $942.00K $1.40M $3.67M
Total Current Liabilities $50.99M $46.47M $32.96M $32.02M $39.50M $32.09M $27.66M
Other Non-current Liabilities $4.04M $2.54M $2.54M $2.54M $3.47M $3.47M $3.47M
Total Liabilities $55.82M $50.08M $37.00M $36.49M $45.34M $37.27M $31.93M
Common Stock $67.00K $66.00K $66.00K $66.00K $66.00K $66.00K $66.00K
Retained Earnings $-1.81B $-1.73B $-1.67B $-1.61B $-1.56B $-1.51B $-1.47B
Total Stockholders Equity $527.16M $598.36M $655.41M $702.98M $747.00M $785.90M $813.66M
Total Liabilities & Equity $582.98M $648.44M $692.41M $739.47M $792.34M $823.18M $845.59M
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Net Income $-81.32M $-67.04M $-56.60M - $-47.09M - -
Depreciation & Amortization $816.00K $2.56M $1.74M $867.00K $819.00K $2.36M $1.57M
Stock-based Compensation $8.91M $27.31M $18.51M $9.32M $9.78M $24.46M $14.84M
Operating Cash Flow $-63.94M $-147.00M $-98.38M $-54.37M $-32.48M $-125.30M $-69.97M
Capital Expenditure $1.28M $1.43M $993.00K $265.00K $756.00K $1.16M $618.00K
Purchases of Investments $54.79M $329.71M $274.08M $151.82M $129.18M $660.75M $560.69M
Investing Cash Flow $55.42M $153.65M $92.80M $42.95M $24.05M $-314.18M $-361.93M
Stock Issued - - - - - $432.30M $432.30M
Financing Cash Flow $1.35M $1.04M $265.00K $202.00K $386.00K $441.06M $439.82M
Net Change in Cash $-7.17M $7.68M $-5.31M $-11.22M $-8.04M $1.58M $7.92M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Total Revenue - - $1.42M -
Operating Expenses $73.62M - $201.64M -
Research & Development $62.93M - $169.74M -
Operating Income $-73.62M - $-200.21M -
Net Income $-67.04M $-35.84M $-177.44M -
Basic EPS -1.01 - -2.67 -
Diluted EPS -1.01 - -2.67 -
Basic Shares Outstanding $66.42K - $66.40K -
Diluted Shares Outstanding $66.42K - $66.40K -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $36.04M $28.36M
Short-term Investments $547.19M $696.92M
Other Current Assets $21.03M $21.18M
Total Current Assets $604.34M $747.16M
Property Plant & Equipment $4.83M $4.35M
Intangible Assets $27.19M $27.19M
Other Non-current Assets $9.36M $9.75M
Total Assets $648.44M $792.34M
Accounts Payable $4.27M $3.27M
Accrued Liabilities $39.72M $33.84M
Other Current Liabilities $930.00K $942.00K
Total Current Liabilities $46.47M $39.50M
Other Non-current Liabilities $2.54M $3.47M
Total Liabilities $50.08M $45.34M
Common Stock $66.00K $66.00K
Retained Earnings $-1.73B $-1.56B
Total Stockholders Equity $598.36M $747.00M
Total Liabilities & Equity $648.44M $792.34M
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-67.04M $-35.84M $-177.44M -
Depreciation & Amortization - - $2.56M -
Stock-based Compensation - - $27.31M -
Operating Cash Flow - - $-147.00M -
Capital Expenditure - - $1.43M -
Purchases of Investments - - $329.71M -
Investing Cash Flow - - $153.65M -
Financing Cash Flow - - $1.04M -
Net Change in Cash - - $7.68M -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-Q filings.

Quarterly data represents single quarter results (Q1-Q4). Some items may show year-to-date values if quarterly breakdown is unavailable.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...